A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea

Hee-Jin Park, Sung Jin Kim, Rok Song, Jing Chen, Joon-Hyung Kim, Raghavendra Devadiga, Hee-Cheol Kang, Hee-Jin Park, Sung Jin Kim, Rok Song, Jing Chen, Joon-Hyung Kim, Raghavendra Devadiga, Hee-Cheol Kang

Abstract

Background: Incidence of whooping cough is increasing in Korea. Since 2011, occurrence among adolescents and adults has risen putting vulnerable neonates at risk. National immunization guidelines now include Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccination during pregnancy and as a cocooning strategy (i.e., vaccinating adults and adolescents in contact with neonates). This study assessed post-marketing Tdap (Boostrix®, GSK, Belgium) vaccine safety in subjects ≥ 10 years.

Methods: This open, non-comparative multi-center study was conducted over six years at 10 hospitals in Korea. Subjects received Tdap in normal clinical practice according to local prescribing information. All adverse events (AEs) were recorded, classified as expected or unexpected, and severity and relationship to Tdap were assessed.

Results: The analysis included 672 Korean subjects (mean age, 44 years; range, 11-81), 451 were women and 211 were pregnant. Ninety subjects experienced 124 AEs (incidence 13.39%) of which six were serious AEs (SAEs) assessed as not related to vaccination, and 51 were non-SAEs related to vaccination (mostly administration site reactions). Overall 65/124 AEs were unexpected; the most common were 14 constipation, 5 dyspepsia, 4 common cold and 4 premature labor cases. One case of common cold was assessed as possibly related to vaccination. Pregnancy outcome was 'live infant, no apparent congenital anomaly' in 195 subjects (92.42%) or 'lost to follow-up' in 16 subjects.

Conclusion: Tdap administration to Korean subjects ≥ 10 years, including pregnant women, for the prevention of diphtheria, tetanus and pertussis was shown to have a well-tolerated safety profile.

Trial registration: ClinicalTrials.gov Identifier: NCT01929291.

Keywords: Korea; Post Marketing Surveillance; Safety; Tdap Vaccine; Whooping Cough.

Conflict of interest statement

Disclosures: Kim SJ, Song R, Chen J, Kim JH, and Devadiga R are employees of the GSK group of companies. Kim SJ, Song R, Chen J, and Kim JH hold shares in the GSK group of companies. Park HJ and Kang HC have nothing to disclose. Involvement of GSK employees did not compromise the scientific integrity of this work.

References

    1. Centers for Disease Control and Prevention (US) Provisional: pertussis surveillance report. [Updated 2017]. [Accessed June 13, 2018]. .
    1. Morgan JL, Baggari SR, McIntire DD, Sheffield JS. Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet Gynecol. 2015;125(6):1433–1438.
    1. Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics. 2015;135(6):e1475–82.
    1. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005;115(5):1422–1427.
    1. Centers for Disease Control and Prevention (US) FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2011;60(37):1279–1280.
    1. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014;312(18):1897–1904.
    1. Centers for Disease Control and Prevention (CDC) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(7):131–135.
    1. Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ. 2014;349:g4219.
    1. Department of Health and Social Care (UK) Pregnant women to be offered whooping cough vaccination. [Updated 2012]. [Accessed June 20, 2018].
    1. Swamy GK, Wheeler SM. Neonatal pertussis, cocooning and maternal immunization. Expert Rev Vaccines. 2014;13(9):1107–1114.
    1. Korean Centers for Disease Control and Prevention. Infectious disease web statistics system. [Updated 2018]. [Accessed November 19, 2018]. .
    1. Choe YJ, Kim JW, Park YJ, Jung C, Bae GR. Burden of pertussis is underestimated in South Korea: a result from an active sentinel surveillance system. Jpn J Infect Dis. 2014;67(3):230–232.
    1. Korean Centers for Disease Control and Prevention. Vaccine preventable infectious disease: epidemiology & management, 5th edition. [Updated 2017]. [Accessed June 20, 2018]. .
    1. Choi KM, Kim KH, Kim YJ, Kim JH, Park SE, Lee HJ, et al. Recommendation for the use of newly introduced Tdap vaccine in Korea. Korean J Pediatr. 2011;54(4):141–145.
    1. Ministry of Food and Drug Safety (KR) Infanrix-IPV prescribing information. [Updated 2017]. [Accessed June 29, 2018]. .
    1. Ministry of Food and Drug Safety (KR) Standard for re-examination of new drugs. [Updated 2015]. [Accessed June 26, 2018]. .
    1. Ministry of Food and Drug Safety (KR) Guideline for re-examination of new drugs. [Updated 2012]. [Accessed January 15, 2018]. .
    1. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309–321.
    1. Klein NP, Hansen J, Lewis E, Lyon L, Nguyen B, Black S, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010;29(7):613–617.
    1. Koo YJ, Ryu HM, Yang JH, Lim JH, Lee JE, Kim MY, et al. Pregnancy outcomes according to increasing maternal age. Taiwan J Obstet Gynecol. 2012;51(1):60–65.
    1. Furuta M, Sin J, Ng ES, Wang K. Efficacy and safety of pertussis vaccination for pregnant women - a systematic review of randomised controlled trials and observational studies. BMC Pregnancy Childbirth. 2017;17(1):390.
    1. Centers for Disease Control and Prevention (US) Guidelines for vaccinating pregnant women. [Updated 2017]. [Accessed January 23, 2019]. .
    1. The Immunisation Advisory Centre (NZ) Boostrix®. [Updated 2018]. [Accessed January 23, 2019]. .
    1. Immunisation and pregnancy - who, what, when and why? Aust Prescr. 2017;40(4):122–124.
    1. National Health Service (UK) Whooping cough vaccination in pregnancy. [Updated 2016]. [Accessed January 23, 2019].

Source: PubMed

3
Předplatit